We aim to realize the value of some of own product candidates ourselves, to retain control and full profitability. To successfully advance products along the clinical development and registration path, we have significantly strengthened our competencies.

Successful implementation of our strategy will propel Zealand forward to a fully integrated biotechnology company, Building on our strong R&D platform while expanding relationships with our customers. Our pipeline will focus on addressing
the needs of patients suffering from gastrointestinal and metabolic diseases, at the same time as incorporating opportunities in other specialty diseases that match our competencies and ambitions.